Genzyme Reports Strong First-Quar... (of this product franchise. -- Sales o...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Genzyme Reports Strong First-Quarter Growth

Date:4/23/2008

of this product franchise.

-- Sales of Sepra(R) products continued to be strong, rising 32 percent to

$30.6 million in the first quarter from $23.1 million in the same

quarter a year ago. The expanded U.S. sales force for Seprafilm(R)

adhesion barrier is reaching a broader range of physicians and helping

drive the product's growth in gynecologic and colorectal surgery.

Future growth of the product in C-section procedures and trauma

surgeries is expected.

-- First-quarter revenue for the Genetics business increased 12 percent to

$74.3 million from $66.2 million, fueled substantially by a higher

volume of reproductive diagnostic testing. The profitability of the

Genetics business is also increasing through improvements in operating

efficiencies, while Genzyme continues to invest in additional

information technology and infrastructure to strengthen the competitive

advantages the business has created. Genzyme Genetics recently

launched carrier and prenatal diagnostic testing for spinal muscular

atrophy, the most common inherited cause of infant mortality. These

tests are expected to support continued profitable growth in subsequent

quarters.

-- Oncology revenue increased 29 percent in the first quarter to $29.0

million from $22.4 million. This growth primarily reflects the

addition of European sales of Clolar, which Genzyme began recording

following its acquisition of Bioenvision Inc. late last year. Genzyme

is working to introduce Clolar worldwide through its global commercial

and regulatory organization. Oncology revenue also reflects growing

first-line use of Campath(R) (alemtuzumab) in the treatment of patients

with B-cell chronic lymphocytic leukemia.

Late-State Development Programs

Genzyme continues to make strong prog
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China

Post Your Comments:

(Date:5/16/2013)... 16, 2013 As the weather warms, women ... favorite Spring looks. While most make a statement with fashion, ... women find the warmer weather mixes makeup and sweat to ... the onset of acne during warmer months, Adult Acne ... treatment users the best ways to deter breakouts. , ...

(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Competitor Analysis: Therapeutic Proteins ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ... The new Competitive ...

(Date:5/16/2013)... Arlington, VA (PRWEB) May 16, 2013 ... for Primary Cells & Stem Cell-Derived Cells: Current and ... low, the number of suppliers in the primary cells ... examines what cell types are used most often, how ... is the market size and anticipated growth rate. ...

(Date:5/16/2013)... Stephen Y. Chou, Founder of Nanonex Corporation, will be ... IEEE Nano 2013 in Beijing, China, on August 5th ... becoming one of the most critical nanofabrication technologies today ... large area, and low cost unmatchable by other nanofabrication ... a broad range of industries, from ICs, nano/micro optical ...

Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7 Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8 BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2 BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3 Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2

[0] Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup [0] Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors [0] BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004)[0] Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013

... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today ... month period ended March 31, 2008., "We ... total of nine,clinical trials, four exploring the use ... use of REOLYSIN(R) in combination with a variety ...

... Squibb,Company (NYSE: BMY ) invites investors and the ... meeting with stockholders at 10 a.m. ET on Tuesday,May ... items to be,transacted, senior executives will review the status ... listen to the webcast, please visit the,Investor Relations page ...

... Training Institute joins the SURGEX(TM) Team, ... Inc., wholly-owned subsidiary of Millennium Biotechnologies,Group, Inc. ... SURGEX(TM) has,become the official sports nutrition drink ... Florida,s premier basketball training facility for,NBA stars ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results Bristol-Myers Squibb Invites Public to Listen to Webcast of 2008 Annual Meeting SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility

(Date:5/18/2013)... Orlando, FL (May 18, 2013) An increasing ... that require interventions to resolve, according to research ... In one study targeting obesity, researchers at the ... have a unique pattern of exhaled breath compared ... in volatile organic compound levels that can be ...

(Date:5/17/2013)... of New Jersey, and City University of New York ... that effectively clears organisms to be viewed under ... hydrate, which is one of the few high-quality clearing ... the Drug Enforcement Administration (DEA) due to its use ... are vital for viewing organisms under a microscope. Without ...

(Date:5/17/2013)... 17, 2013, Shenzhen, China---- Why Tibetan antelope can ... Plateau? In a collaborative research published in ... and other institutes provide evidence that some genetic ... to harsh highland environments. The data in this ... genetic mechanisms and the biology of other ruminant ...

Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2 New research identifies risks, interventions for children's GI health 3 New formula invented for microscope viewing, substitutes for federally controlled drug 2 New formula invented for microscope viewing, substitutes for federally controlled drug 3 The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2

[0] New research identifies risks, interventions for children's GI health [0] New formula invented for microscope viewing, substitutes for federally controlled drug [0] The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation

... 15, 2012 ChromaDex Corporation (OTCBB: CDXC) an ... solutions and ingredients to the dietary supplement, food ... financial results for the fiscal year ended December ... accordance with United States Generally Accepted Accounting Principles ...

... , , , , , , ... , , AUDIO: This ... , Click here for more information. , ... , , , , ...

... with conservation tillage increases, more growers are encountering slugs, ... virtually all crops, and they are challenging to control ... are available. In "Slug (Mollusca: Agriolimacidae, Arionidae) Ecology ... on the mid-Atlantic Region," a free, open-access article appearing ...

Cached Biology News:ChromaDex® Announces Financial Results for the Year Ended 2011 2 ChromaDex® Announces Financial Results for the Year Ended 2011 3 ChromaDex® Announces Financial Results for the Year Ended 2011 4 ChromaDex® Announces Financial Results for the Year Ended 2011 5 Common North American frog identified as carrier of deadly amphibian disease 2 Common North American frog identified as carrier of deadly amphibian disease 3 Common North American frog identified as carrier of deadly amphibian disease 4

ChromaDex® Announces Financial Results for the Year Ended 2011 Common North American frog identified as carrier of deadly amphibian disease Slug ecology and management in no-till field crops

... stored within neurons in vesicles called ... the synaptic bouton. Synaptosomes may ... from other cellular debris. Abnormalites in ... many pathological condtions. Conditions of ...

... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...

... of your microarray data using Asuragens ... you need from consultation to extensive ... to date methods. Utilize our expertise ... Profiling Service or from your own ...

... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...

Biology Products:

Superfusion System, Raiteri's Method from myNeuroLab.com Corning Roller Bottle Easy Grip Caps, Sterile from Sigma-Aldrich Affymetrix Standard Data Analysis Report from Asuragen, Inc.CORNING ROLLER BOTTLE, 850CM2, PS, EASY GRIP CAP, GRADUATED from Sigma-Aldrich